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TABLE 3. The lack of int1uence of age of donors on (OICfllll(,C induction in BLO mice 
-----------~--------------~------~~~~--~~-----------CP 1:31O.BR skin graft Nil. Spleen cpils MST±SD Hecipient" Group (5x 10"/g) (:lOll fll~/kgF survival (inys) mice 
BI0.BR(6w) 
B10.BR(6w) + 
BlO.BR(l2w) 
B10(8w) BI0.BR(12w) + 
B10.BR(37w) 
BI0.BR(37w) + 
• See footnote" of Table 1. 
b Not significant compared with group 2 by the U test. 
by complexities related to the tolerogenic spleen cell popula-
tions, as already indicated in another study of this series.3 
Namely, in the induction oftolerance with the combined treat-
ment of allogeneic spleen cells plus CP, the antigenicity of the 
spleen cells, the numbers of T cells. and the numbers. of Ia 
positive cells also may be as crucial as the numbers of the stem 
cells contained in the preparation. 
In summary, the age of adult recipient mice was found crucial 
to the induction of skin allograft tolerance with allogeneic 
spleen cells plus CP. By contrast. the age of the donor mice 
used for tolerance induction did not appear to be crucial for the 
induction of a tolerant state. 
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FK506: A NOVEL IMMUNOSUPPRESSIVE AGENT 
CHARACTERISTICS OF BINDrNG AND UPTAKE BY HUMAN LYMPHOCYTES 
Several studies indicate FK506, a novel compound (Fig. 1). 
to be a potent immunosuppressive agent (1). Like cyclosporine, 
FK506 is isolated from a fungus. Streptomyces tsukubaensis, 
and is hydrophobic. Although cyclosporine is a peptide of larger 
molecular weight than FK506. both are cyclic compounds, with 
cyclosporine being more rigid than FK506. Recent in vitro 
studies suggest that FK506 possesses immunosuppressive prop-
erties similar to those of cyclosporine, implying that the mech-
anism of action for these two drugs may be similar as well. The 
immunosuppressive effect of FK506 is several-hundred-fold 
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FIGURE 1. FK506. 
greater than that of cyclosporine (2,3). As previously demon-
strated for cyclosporine, the inhibitory effect of FK506 is seen 
in mixed leukocyte culture and on secondary proliferation of 
alloreactive T cells harvested from MLC or propagated- from 
organ transplant biopsies (4). The published data further show 
that immunosuppression by FK506 may be mediated through 
an inhibition of interleukin-2 release (2, 4), again emphasizing 
the similarities between cyclosporine and FK506. 
In this report we describe the characteristics and kinetics of 
cellular uptake and intracellular binding of FK506 by human 
peripheral blood lymphocytes. PBL were isolated from the 
blood of four healthy donors and depleted of their monocyte 
content as described previously (5). 
Binding and uptake of FK506 by PBL is shown in Figure 2. 
The uptake of FK506 by PBL is a saturable process, with 
saturation occurring at an approximately O.S ~M concentration 
of the drug. Scatchard analysis of the binding data is consistent 
with two distinct classes of binding sites-one with a ~ = 
3.9±1.8xlO-B M for the high affinity sites, and the second with 
a Kd = S.2±0.8xI0-6 M for the low affinity sites. This analysis 
further reveals that there are 5.6±1.0xl04 and 2.5±0.9x106 
high- and low-affinity binding sites, respectively, per cell. 
LeGrue et al. (7) have reported that binding of cyclosporine by 
normal PBL also exhibits two classes of binding sites with a 
~ of 2-6x10-9 M for the high-affinity site and a Kd of about 
10-1 M representing a low-affinity site. They have further 
indicated that only B cells possess high-affinity sites. Our data, 
together with this information, seem to further delineate the 
similarities between FKS06 and cyclosporine. 
Merker and Handschumacher (8) have studied the intracel-
lular localization of cyclosporine by a murine thymoma cell line 
(BWS147), and have shown that cyclosporine binds to a cyto-
solie protein (termed cyclophilin) with an apparent molecular 
weight of 1S,000-20,000 daltons. More recently, Fabre et a!. (9) 
have shown the presence of a similar protein in a human 
Burkitt lymphoma cell line (RAJI cells). The dissociation con-
stant for the binding of cyclosporine to cyclophilin has been 
reported to be approximately 2.2 ~MK We have investigated the 
binding of FK506 to cytosolic proteins obtained from PBL. 
The elution profile of FK506 and cyclosporine on a Bio-Gel 
P-60 exclusion column that had been calibrated with ovalbu-
min, carbonic anhydrase, cytochrome C, and vitamin BI2 is 
shown in Figure 3. A graph of the log molecular weight versus 
the ratio of the elution volume to the void volume for the 
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FIGURE 2. Binding of FK506 by human peripheral blood lympho-
c~sK Normal human lymphocytes (5x108) were incubated for 60 min 
at 37'C in 250 iLl of 1% BSA-RPMI 1640 medium containing the 
indicated concentrations of FK50G. The cells were chilled at O'C for 10 
min and washed twice with cold saline, resuspended in phosphate 
buffer (0.2 M, pH 7.4), and the suspension was used for FK506 
determination using the Fujisawa method (6). Results are in iLmoljl0" 
cells. 
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FIGURE 3. Elution profile of the intracellular proteins of PBL on 
Bio-Gel poGO. Normal human lymphocytes (100X106) cells were incu-
bated for 60 min at 37'C in 4 ml 1% BSA-RPMI 1640 medium 
containing 2 ILg FK506 and 1.5 ILg (,H) cyclosporine (specific activity 
300 dpm/ng). The cells were chilled at O'C for 10 min, washed twice 
with cold saline, and resuspended in Tris buffer (20 mM, pH 7.2) 
containing 2-mercaptoethanol (5 mMl and sodium azide (0.02%). CeJls 
were disrupted by sonic oscillation (9), the cellular debris was removed 
by centrifugation at 40,000 g for 30 min, and the supernate was passed 
through a Bio-Gel P-6 column to remove protein·free FK506 and 
cyclosporine. The drugs were then chromatographed on a Bio-Gel 
P-60 column (40 ern x 1.5 em) using the same Tris buffer. Utilizing 
the calibration curve of the molecular weight markers-Cal ovalbumin, 
(b) carbonic anhydrase, (c) cytochrome C and (d) vitamin Bl2-as 
described in the insert, it appears that both cyclosporine (6) and FK506 
(e) are associated with a protein or proteins with a molecular weight 
around 18,000-19,000 daltons. 
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molecular weight markers is shown in the insert. These data 
suggest that both FK506 and cyclosporine elute in association 
with a protein with an apparent molecular weight of approxi-
mately 18,000-19,000 daltons. Whether this is incidental or 
there is in fact only one protein that binds both drugs is not 
clear at present. But, if a single protein, such as cyclophilin, is 
involved in the binding of both these drugs, then the question 
of whether two separate binding sites are involved in this 
process remains to be investigated. Recently, we have demon-
strated that human PBL exposed to FK506 for periods varying 
from 1 hr to 40 hr are able to take up about 20% more 
cyclosporine relative to control cells 'not exposed to FK506 
(10). Similarly, FK506 exposed cells show considerably in-
creased sensitivity to cyclosporine (2-4) in terms of mixed 
lymphocyte reaction and primed lymphocyte tests. This evi-
dence seems to suggest that binding of one drug, for instance 
FK506, modifies the cellular response to another drug (cyclo-
sporine), resulting in a greater uptake of cyclosporine by the 
cell. 
In summary, kinetics of binding and uptake of FK506 by 
PBL, and the apparent common association of FK506 and 
cyclosporine with an intracellular protein, enhances further the 
similarities between these two immunosuppressive agents. 
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AUTOMATED ISOLATION OF MOUSE PANCREATIC ISLETS1 
The development of an automated method for the isolation 
of human pancreatic islets (1) demonstrated that it is possible 
to obtain large numbers of intact islets with minimal traumatic 
action to the islets through a continuous digestion process in 
which the islets are progressively liberated and saved from the 
collagenase action. One of the advantages of this procedure is 
to avoid any chopping, teasing, aspiration through needles, or 
tissue maceration used in other procedures (2-8) that could 
result in a considerable traumatic action to the islets. In addi-
tion, with other isolation procedures, the predigestion of diges-
tion process is generally stopped at an estimated optimal diges-
tion time, and the isolation is then continued by other means. 
When the pancreatic digestion is interrupted, part of the pan-
creas is generally still undigested, other portions are overdi-
gested, and what is left is the portion of the preparation that 
at the time is optimally dissociated: islets free from exocrine 
tissue but not yet damaged by the collagenase activity. 
I This work was supported by NIH Grant DK-01226-31 and by NIH 
Training Program Grant 5T32AI07163. 
The viability of human islets isolated by the automated 
method has been tested already in different models (9-11) that 
demonstrated the functional integrity of the islets obtained by 
this procedure. After these encouraging results, it was decided 
to test a similar procedure for mouse islet isolation in order to 
determine whether the number of donor mice required to make 
a recipient normoglycemic could be reduced. Our original col-
lagenase technique (12) for mouse islet isolation required 24 
mice to obtain approximately 1,200 islets for transplantation. 
In addition, a small scale model of the automated isolation 
procedure would be useful for the isolation of islets from other 
small animals, or for the digestion of fetal or neonatal pancre-
ases of larger mammals, including man. 
Six male BIO.BR/SgSnJ (BIO.BR) mice, 5-8 weeks old, were 
used for each isolation. Under nembutal anesthesia, the mice 
were opened by a midline incision. The bile duct was clamped 
near the duodenum and the pancreas distended by intraductal 
injection (30-gauge needle) in the proximal common bile duct 
of 2 ml cold (4°C) Hanks' balanced salt solution containing 1 
mg/ml collagenase (Sigma, Type Xl). Six pancreases were then 
